Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

Launched by AIN SHAMS UNIVERSITY · May 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called dapagliflozin to see if it can help people with advanced chronic kidney disease (CKD) by slowing down the decline in kidney function and reducing the risk of serious health issues related to the heart and kidneys. The trial is looking for adults aged 18 and older who have advanced CKD but are not on dialysis. Unfortunately, people with certain conditions, like type 1 diabetes or those who have specific health issues related to their kidneys, cannot participate.

If you join this trial, you will take either dapagliflozin or a placebo (a pill that looks the same but has no active medication) to help researchers compare the two. This study is important because it aims to understand better how dapagliflozin can improve health outcomes for people with advanced CKD, which is a serious condition. The trial is currently recruiting participants, and both men and women are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients aged eighteen or older.
• • Patients with advanced chronic kidney disease (i.e., eGFR \< 20 mL/min/1.73m2)not on dialysis
• Exclusion Criteria:
• • Autosomal dominant polycystic kidney disease (ADPKD).
• • Type 1 diabetes mellitus
• • Patients on SGLT2 inhibitors.
• • History of ketoacidosis in the last 3 months.
• • Known hypersensitivity to SGLT2 inhibitors.
• • Known hepatic impairment.
• • Pregnant or breastfeeding females.